Expansion of Management Team at Hermes Arzneimittel

Hermes Arzneimittel, a prominent player in the German OTC pharmaceutical sector based in Pullach im Isartal, is set to enhance its management team to better align with its future growth ambitions. The company, recognized as a leading manufacturer in the over-the-counter market, aims to adapt to the increasing complexity of market demands.

Starting July 1, 2025, the leadership responsibilities will be shared between Thomas Stadler and the newly appointed Tobias Brodtkorb. This strategic decision reflects the company's commitment to structural development in response to expanding roles and requirements within the industry.

Tobias Brodtkorb brings a wealth of experience to his new role, having spent two decades advising health sector companies on market positioning at Sempora Consulting. His expertise encompasses strategy, marketing, and sales. Most recently, he led SymbioPharm, a firm specializing in microbiome research and probiotics, to significant success. Before his tenure at Sempora, Brodtkorb held various marketing and sales positions at well-known companies such as Schneekoppe and Reckitt Benckiser.

Under Thomas Stadler's leadership since 2021, Hermes Arzneimittel has achieved remarkable financial growth, reporting revenues exceeding EUR183 million. This achievement underscores the company's robust market presence and potential for future expansion.

The decision to broaden the management team is a proactive step to ensure Hermes Arzneimittel remains competitive and responsive to the dynamic healthcare market. The company is poised to leverage Brodtkorb's extensive industry knowledge to navigate the complexities of the evolving pharmaceutical landscape.